PMID- 21039412
OWN - NLM
STAT- MEDLINE
DCOM- 20110517
LR  - 20181201
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Linking)
VI  - 164
IP  - 3
DP  - 2011 Mar
TI  - A systematic review of drug-induced subacute cutaneous lupus erythematosus.
PG  - 465-72
LID - 10.1111/j.1365-2133.2010.10110.x [doi]
AB  - The initial appearance of subacute cutaneous lupus erythematosus (SCLE) skin 
      lesions in conjunction with Ro/SS-A autoantibodies occurring as an adverse 
      reaction to hydrochlorothiazide [i.e. drug-induced SCLE (DI-SCLE)] was first 
      reported in 1985. Over the past decade an increasing number of drugs in different 
      classes has been implicated as triggers for DI-SCLE. The management of DI-SCLE 
      can be especially challenging in patients taking multiple medications capable of 
      triggering DI-SCLE. Our objectives were to review the published English language 
      literature on DI-SCLE and use the resulting summary data pool to address 
      questions surrounding drug-induced SCLE and to develop guidelines that might be 
      of value to clinicians in the diagnosis and management of DI-SCLE. A systematic 
      review of the Medline/PubMed-cited literature on DI-SCLE up to August 2009 was 
      performed. Our data collection and analysis strategies were prospectively 
      designed to answer a series of questions related to the clinical, prognostic and 
      pathogenetic significance of DI-SCLE. One hundred and seventeen cases of DI-SCLE 
      were identified and reviewed. White women made up the large majority of cases, 
      and the mean overall age was 58.0 years. Triggering drugs fell into a number of 
      different classes, highlighted by antihypertensives and antifungals. Time 
      intervals ('incubation period') between drug exposure and appearance of DI-SCLE 
      varied greatly and were drug class dependent. Most cases of DI-SCLE spontaneously 
      resolved within weeks of drug withdrawal. Ro/SS-A autoantibodies were present in 
      80% of the cases in which such data were reported and most remained positive 
      after resolution of SCLE skin disease activity. No significant differences in the 
      clinical, histopathological or immunopathological features between DI-SCLE and 
      idiopathic SCLE were detected. There is now adequate published experience to 
      suggest that DI-SCLE does not differ clinically, histopathologically or 
      immunologically from idiopathic SCLE. It should be recognized as a distinct 
      clinical constellation differing clinically and immunologically from the 
      classical form of drug-induced systemic lupus erythematosus.
CI  - (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists.
FAU - Lowe, G C
AU  - Lowe GC
AD  - University of Utah School of Medicine, Salt Lake City, USA.
FAU - Henderson, C L
AU  - Henderson CL
FAU - Grau, R H
AU  - Grau RH
FAU - Hansen, C B
AU  - Hansen CB
FAU - Sontheimer, R D
AU  - Sontheimer RD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20110217
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticonvulsants)
RN  - 0 (Antifungal Agents)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biological Products)
RN  - 0 (Histamine Antagonists)
RN  - 0 (Immunologic Factors)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
EIN - Br J Dermatol. 2014 Apr;170(4):999. Lowe, G [corrected to Lowe, G C]
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Anticonvulsants/adverse effects
MH  - Antifungal Agents/adverse effects
MH  - Antihypertensive Agents/adverse effects
MH  - Antineoplastic Agents/adverse effects
MH  - Biological Products/adverse effects
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - Histamine Antagonists/adverse effects
MH  - Humans
MH  - Immunologic Factors/adverse effects
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/immunology/pathology
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/adverse effects
MH  - Ultraviolet Therapy/adverse effects
EDAT- 2010/11/03 06:00
MHDA- 2011/05/18 06:00
CRDT- 2010/11/03 06:00
PHST- 2010/11/03 06:00 [entrez]
PHST- 2010/11/03 06:00 [pubmed]
PHST- 2011/05/18 06:00 [medline]
AID - 10.1111/j.1365-2133.2010.10110.x [doi]
PST - ppublish
SO  - Br J Dermatol. 2011 Mar;164(3):465-72. doi: 10.1111/j.1365-2133.2010.10110.x. 
      Epub 2011 Feb 17.